<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595997</url>
  </required_header>
  <id_info>
    <org_study_id>DLX105-003-001-001</org_study_id>
    <nct_id>NCT01595997</nct_id>
  </id_info>
  <brief_title>Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris</brief_title>
  <acronym>2011-00500-15</acronym>
  <official_title>A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delenex Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delenex Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to support the development of a DLX105 topical&#xD;
      formulation for the indication mild to moderate psoriasis vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability: Investigator's assessment of local tolerability using a validated score for each treatment area. Patient's assessment of subjective tolerability sensations (burning, itching, pain) recorded on a visual analogue scale (VAS) (0-10</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables:</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events Detection of anti-drug antibodies (ADAs). Assessment of immunogenic potential of DLX105 by ELISA with coated DLX105 to capture anti-DLX105 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy variables</measure>
    <time_frame>28 days</time_frame>
    <description>clinical signs of pharmacodynamic activity to intra-dermal administration of DLX105</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild-to-moderate Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DLX105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLX105</intervention_name>
    <description>intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10</description>
    <arm_group_label>DLX105</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated Informed Consent&#xD;
&#xD;
          -  Male or female Caucasian patients with stable chronic mild-to-moderate plaque-type&#xD;
             psoriasis (PASI ≤15) aged 18-75 years who must have at least two pronounced but not&#xD;
             active lesions of &gt;9 cm2 each, stable for at least 3 months, local PASI score ≥8.&#xD;
             Distance between lesions must be at least 30 cm.&#xD;
&#xD;
          -  Affected body surface area (BSA) ≤10%&#xD;
&#xD;
          -  Negative pregnancy test for females of child bearing potential (pre-menopausal, &lt;2&#xD;
             years post-menopausal, not surgically sterile)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and&#xD;
             guttate psoriasis, palmar, plantar or nail disease) at screening&#xD;
&#xD;
          -  Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers,&#xD;
             calcium channel inhibitors or lithium) prior to randomization&#xD;
&#xD;
          -  Ongoing use of psoriasis treatments (duration of washout, i.e. discontinuation prior&#xD;
             to randomization):&#xD;
&#xD;
          -  Alefacept (6 months)&#xD;
&#xD;
          -  Biological agents other than alefacept, e.g. adalimumab, efalizumab, etanercept,&#xD;
             infliximab, ustekinumab (12 weeks)&#xD;
&#xD;
          -  Systemic therapy for psoriasis and psoriatic arthritis (other than above) e.g.&#xD;
             methotrexate, cyclosporin, fumaric acid (derivatives), systemic steroids (4 weeks)&#xD;
&#xD;
          -  Photochemotherapy e.g., ultraviolet A with psoralen (PUVA) (4 weeks)&#xD;
&#xD;
          -  Phototherapy e.g., ultraviolet A (UVA) or ultraviolet B (UVB) (2 weeks)&#xD;
&#xD;
          -  Topical treatments, except in face, scalp and genital area during screening (2 weeks)&#xD;
&#xD;
          -  Other investigational psoriasis drugs (4 weeks or 5 half-lives, whichever is longer)&#xD;
&#xD;
          -  Ongoing use of other (non-psoriasis) treatments (duration of washout, i.e.&#xD;
             discontinuation prior to randomization):&#xD;
&#xD;
          -  Investigational drugs, not psoriasis drugs (4 weeks or 5 half-lives, whichever is&#xD;
             longer)&#xD;
&#xD;
          -  Known immunosuppression&#xD;
&#xD;
          -  History or evidence of active tuberculosis. All patients will be tested for&#xD;
             tuberculosis status using a blood test (QuantiFERON TB-Gold) unless this test has been&#xD;
             performed within 4 months prior to randomization and was negative. Patients with&#xD;
             evidence of latent tuberculosis may enter the trial after sufficient treatment has&#xD;
             been initiated according to local regulations.&#xD;
&#xD;
          -  Active systemic infections (other than common cold) during the two weeks before&#xD;
             randomization&#xD;
&#xD;
          -  Positive test for hepatitis B or C at screening&#xD;
&#xD;
          -  Positive test for HIV at screening&#xD;
&#xD;
          -  History or symptoms of malignancy of any organ system (other than history of basal&#xD;
             cell carcinoma and / or up to three squamous cell carcinomas of the skin, if&#xD;
             successful treatment has been performed, with no signs of recurrence; actinic&#xD;
             keratoses, if present at screening, should be treated according to standard therapy&#xD;
             before randomization), treated or untreated, within the past 5 years, regardless of&#xD;
             whether there is evidence of local recurrence or metastases.&#xD;
&#xD;
          -  History of severe hypersensitivity to any human or humanized biological agents&#xD;
&#xD;
          -  Any severe, progressive or uncontrolled medical condition at baseline that in the&#xD;
             judgment of the investigator prevents the patient from participating in the study&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory tests at baseline&#xD;
&#xD;
          -  Active liver disease with alanine aminotransferase (ALT) and / or aspartate&#xD;
             aminotransferase (AST) &gt; 3 x upper limit of normal&#xD;
&#xD;
          -  History of moderate or severe congestive heart failure (New York Heart Association&#xD;
             [NYHA] class III or IV).&#xD;
&#xD;
          -  Inability or unwillingness to undergo repeated venipunctures (e.g., due to poor&#xD;
             tolerability or lack of access to veins)&#xD;
&#xD;
          -  History or evidence of drug or alcohol abuse within the 6 months prior first study&#xD;
             drug administration&#xD;
&#xD;
          -  Patients who had live vaccination within 6 weeks prior first study drug&#xD;
             administration, or will require live vaccination during the course of the trial&#xD;
&#xD;
          -  History of hypersensitivity to any of the excipients of the study drug or to&#xD;
             excipients of similar chemical classes&#xD;
&#xD;
          -  History of hypersensitivity to any active ingredient of similar chemical entity&#xD;
             (polypeptides)&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (HCG) laboratory test (&gt; 5 mIU/mL)&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant. UNLESS they are&#xD;
&#xD;
          -  Women whose partners have been sterilized by vasectomy or other means&#xD;
&#xD;
          -  Using a highly effective method of birth control (i.e. one that results in a less than&#xD;
             1% per year failure rate when used consistently and correctly, such as implants,&#xD;
             injectables, combined oral contraceptives, condoms (by the partner), and some&#xD;
             intrauterine devices (IUDs)). Periodic abstinence (e.g. calendar, ovulation,&#xD;
             symptothermal, post-ovulation methods) and withdrawal are not considered acceptable&#xD;
             forms of birth control within this study.&#xD;
&#xD;
          -  Reliable contraception should be maintained throughout the study and for 12 weeks&#xD;
             after the last study drug administration&#xD;
&#xD;
          -  Participation in any other clinical trial within 4 weeks prior to or during this trial&#xD;
&#xD;
          -  Exposure to DLX105 / ESBA105 in previous studies of this antibody fragment or in Part&#xD;
             A of this study (i.e. the same patient cannot participate in Part A and B)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster (UKM)</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into psoriatic lesion of mild-to-moderate psoriatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

